Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, seem to align with recent bad news for this ...

Lou explained that while immune checkpoint inhibitors and T cell-based therapies have been successful in non-small cell lung ...

Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...

Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer ...

Patients older than 65 years had similar clinical outcomes in response to immune checkpoint inhibitors as younger patients with cancer.

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical ...

Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...